Skip to content
Peptide research

Vesugen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

What it is

A tripeptide bioregulator (lysine-glutamate-aspartate) marketed for vascular and endothelial health and slower biological aging. Evidence is mostly mechanistic and animal-based, with rejuvenation and blood-flow claims resting on preliminary laboratory findings and small human studies. Human safety data is very limited, independent validation is lacking, and prooxidant activity has been seen. Available products are unregulated, and Vesugen is not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Vascular endothelial cell rejuvenation and Ki-67 restoration

    Low

    Restored a proliferation marker in cultured endothelial cells; not tested in vivo or in humans.

  • Improved peripheral vascular blood flow in elderly patients

    Speculative

    A small before-and-after study reports improved lower-limb blood-flow measures in 41 patients; causal benefit remains uncertain.

  • Neuroimmunoendocrine cell proliferation and anti-apoptotic effects

    Low

    Shown only in one lab's rat tissue culture study, not confirmed in living animals or humans.

Evidence limits

Evidence Level
Limited Evidence

Human evidence for Vesugen is extremely limited, consisting primarily of small Russian clinical studies without randomization, blinding, or placebo controls. Two vascular reports each describe 41 patients. PMID 28976154 concerns lower-limb ischemia; despite its title, PMID 25051774 describes vasculogenic erectile dysfunction and penile blood flow. Participant overlap is unknown. The geroprophylaxis study (PMID 26390612) enrolled 32 patients and measured biological aging markers. These studies are suggestive but methodologically weak by Western standards. The majority of Vesugen evidence (~85%) comes from in vitro cell culture and animal models. No independent Western research groups have replicated the clinical findings.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(7)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Very limited human safety data

    High
  • Lack of independent safety validation

    High
  • Prooxidant activity observed

    Moderate
  • Research-grade product quality concerns

    Moderate
  • Mild gastrointestinal effects

    Low
  • Injection site reactions (injectable form)

    Low
  • Hematopoietic suppression signal

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.